All In Biotech

Drug Trial Radar · NCT05296447

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy

A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of Suprachoroidal Administration of RGX-314 for Diabetic Retinopathy With and Without Center Involved-Diabetic Macular Edema

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

103

Actual

Start

Apr 4, 2022

Primary completion

Jun 2031

Study completion Jun 2031

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
Collaborators
REGENXBIO Inc.
First posted
Mar 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of DR with and without center involved-diabetic macular edema (CI-DME) in which they received suprachoroidal space (SCS) administration of ABBV-RGX-314. Enrollment of each participant in the current study should occur after the participant has completed either the end of study or early discontinuation visit in the previous (parent) clinical study. Participants will be followed for a total of 5 years post-ABBV-RGX-314 administration (inclusive of the parent study). As such, the total study duration for each participant may vary depending on when they enroll in the current study following ABBV-RGX-314 administration in the parent study.

Conditions

  • Diabetic Retinopathy, DR

Interventions

  • Standard of CareDrug

    Standard of Care

  • AfliberceptDrug

    Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of ocular adverse events (AEs) and any serious adverse events (SAEs)Time frame: 5 years inclusive of the parent study

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Retinal Research Institute, LLC

    Phoenix, Arizona

  • California Retina Consultants

    Bakersfield, California

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California

  • Retinal Diagnostic Center

    Los Angeles, California

  • Northern California Retina Vitreous Associates Medical Group Inc

    Mountain View, California

  • California Eye Specialists Medical Group, Inc

    Pasadena, California

  • Retina Consultants San Diego

    Poway, California

  • California Retina Consultants CRC

    Santa Barbara, California

  • Southeast Retina Center, PC

    Augusta, Georgia

  • University Retina and Macula Associates, PC

    Oak Forest, Illinois

  • Cumberland Valley Retina Consultants

    Hagerstown, Maryland

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts

  • Sierra eye Associates

    Reno, Nevada

  • New Jersey Retina

    Teaneck, New Jersey

  • Vision Research Center Eye Associates of New Mexico

    Albuquerque, New Mexico

  • Duke University

    Durham, North Carolina

  • Mid Atlantic Retina

    Philadelphia, Pennsylvania

  • Charles Retina Institute, P.C

    Germantown, Tennessee

  • Austin Clinical Research

    Austin, Texas

  • Retina Consultants of Texas

    The Woodlands, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.